SCHEMBL2950026

SCHEMBL2950026

CN(C)C1CCC(C(=O)Nc2c(C(=O)Nc3ccc(Cl)cn3)oc3ccc(C(=O)O)cc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ F10 P00742 5/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ WNT1 P04628 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ TSHR P16473 4/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ DHODH Q02127 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950030 1.00 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10KDM4E
SCHEMBL2944612 0.92 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AF10KDM4E
SCHEMBL2944611 0.92 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AF10KDM4E
SCHEMBL4331028 0.92 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10KDM4E
SCHEMBL4331029 0.92 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10KDM4E
SCHEMBL13863934 0.91 NPC1 (0.46) SMN1; SMN2MEN1KMT2AKDM4EALDH1A1
SCHEMBL13753160 0.91 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AF10KDM4E
Hydrochloric Acid SCHEMBL2945742 0.90 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2AF10KDM4E
Hydrochloric Acid SCHEMBL2945745 0.90 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2AF10KDM4E
SCHEMBL2941131 0.89 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 — — EP disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 — — US disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 SMN1; SMN2 3151/4885MEN1 2756/4885KMT2A 1500/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885MEN1 2864/4885KMT2A 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback